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Background: Previously, we reported that autoantibodies specific for the angiotensin II type I receptor (anti-AT1-AR) is implicated in the pathology 
of congestive heart failure (CHF). We hypothesized that the presence of anti- AT1-AR is associated with left ventricular (LV) function of CHF patients in 
response to perindopril, which is a long-acting angiotensin-converting-enzyme inhibitor.
methods: Synthetic angiotensin AT1 receptor (AT1-AR) peptides served as the target antigen in ELISA was used to screen the sera of 156 
CHF patients, then patients were divided into positive (+) anti- AT1-AR or negative (-) anti- AT1-AR groups based on their anti- AT1-AR reactivity. 
Echocardiography and 6-minute walk distance were performed at baseline and after one year of perindopril therapy in combination with metoprolol, 
diuretics and digoxin in both group.
results: A total of 138 patients completed the final analysis in this study, including 82 patients with (+) anti- AT1-AR and 56 patients with (-) 
anti- AT1-AR. Compared to the patients with (-) anti- AT1-AR, patients with (+) anti- AT1-AR had a greater improvement in LV end-diastolic and end-
systolic dimensions (all p<0.001), as well as 6-minute walk distance (p<0.001) after one year of perindopril therapy in combination with metoprolol, 
diuretics and digoxin treatment. Interestingly, the presence of (+) anti- AT1-AR resulted in a greater improvement in LV remodeling and function 
compared to (-) anti- AT1-AR (p<0.001). The combined endpoint event was significant lower in patients with (+) anti- AT1-AR than that in patients 
with (-) anti- AT1-AR (p<0.05, 36.5% vs. 69.9%).
conclusions: In patients with (+) anti- AT1-AR, compared with (-) anti- AT1-AR patients, same dose of the perindopril, has a better clinical 
therapeutic effect on congestive heart function so as to decrease the combined endpoint events. This result potentially presents a novel biomarker 
of the renin-angiotensin-aldosterone system for the detection as well as therapeutic intervention of congestive heart failure patients.
